Protagonist Therapeutics (PTGX) Receivables (2017 - 2026)

Protagonist Therapeutics (PTGX) has 10 years of Receivables data on file, last reported at $57.1 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables changed N/A year-over-year to $57.1 million; the trailing twelve-month figure through Mar 2026 stood at $57.1 million (changed N/A YoY), and the FY2025 full-year result was $4.5 million, down 97.33% from the prior year.
• Receivables improved to $57.1 million in Q1 2026, from $4.5 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $168.2 million in Q4 2024 to a low of $52000.0 in Q4 2022.
• A 5-year average of $26.2 million and a median of $2.6 million in 2022 frame the typical range for Receivables.
• Across the five-year window, Receivables soared 220.65% in 2022 and tumbled 99.6% in 2023, its largest moves.
• Tracing PTGX's Receivables over 5 years: stood at $52000.0 in 2022, then jumped by 50.0% to $78000.0 in 2023, then surged by 215594.87% to $168.2 million in 2024, then sank by 97.33% to $4.5 million in 2025, then surged by 1173.34% to $57.1 million in 2026.
• Business Quant data shows PTGX's Receivables at $57.1 million in Q1 2026, $4.5 million in Q4 2025, and $5.1 million in Q3 2025.